Abstract
The widely used nasally-administered Live Attenuated Influenza Vaccine (LAIV) alters the dynamics of naturally occurring nasopharyngeal carriage of Streptococcus pneumoniae in animal models. Using a human experimental model (serotype 6B) we tested two hypotheses: 1) LAIV increased the density of S. pneumoniae in those already colonised; 2) LAIV administration promoted colonisation. Randomised, blinded administration of LAIV or nasal placebo either preceded bacterial inoculation or followed it, separated by a 3-day interval. The presence and density of S. pneumoniae was determined from nasal washes by bacterial culture and PCR.
Overall acquisition for bacterial carriage were not altered by prior LAIV administration vs. Bacterial carriage densities were increased approximately 10-fold by day 9 in the LAIV recipients (2.82 vs 1.81 log 10 titers, p=0.03). When immunisation followed bacterial acquisition (n=163), LAIV did not change area under the bacterial density-time curve (AUC) at day 14 by conventional microbiology (primary endpoint), but significantly reduced AUC to day 27 by PCR (p=0.03). These studies suggest that LAIV may transiently increase nasopharyngeal density of S.
pneumoniae. Transmission effects should therefore be considered in the timing design of vaccine schedules. Pneumonia kills more children under 5 than any other illness, and is in part preventable by immunization. 1 In the elderly, community-acquired pneumonia is a leading cause of mortality,
with Streptococcus pneumoniae (the pneumococcus) the most common etiologic agent 2 . The nasopharynx is colonized by the pneumococcus, and serves as the primary reservoir for humanhuman transmission'; this "carriage" necessarily precedes invasive infection. Influenza infection increases pneumococcal carriage density and dysregulates host immune responses. During influenza epidemics, this causes secondary bacterial pneumonia and increases mortality. [3] [4] [5] Live Attenuated Influenza Vaccine (LAIV), a nasal spray, has been used in the United States since 2003 for influenza prevention in children and adults, and its eligibility for use for the 2018-19 season has been confirmed by the Center for Disease Control (CDC). In the United Kingdom, annual single-dose LAIV given to children aged 2-16 years since 2013 has significantly reduced severe influenza disease. 6 Pre-licensure and early post-marketing surveillance data showed that LAIV-protection was comparable to inactivated vaccines.
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Animal models of influenza infection demonstrate increased density and duration of pneumococcal carriage. Experimental human influenza infection increases carriage rates. 3, 4, 8 In mice, LAIV vaccination increases the density and duration of pneumococcal carriage, and rates of otitis media. 9, 10 In children, LAIV is associated with increased rates and density of bacterial carriage. 11 Whilst LAIV is safe and not associated with increases in pneumococcal disease, these data suggest it could increase pneumococcal transmission to susceptible individuals.
12,13
We used an established experimental pneumococcal challenge model to evaluate the effect of LAIV on pneumococcal carriage acquisition, density and duration. We report two trials representing distinct scenarios in the community setting: 1) Antecedent immunisation -individuals acquire pneumococcus following LAIV vaccination, in the period when nasopharyngeal viral replication takes place; 2) Concurrent immunisation -individuals already colonised with the bacteria are administered LAIV. (Table S1 ). LAIV participants received a median 74,500 CFU/nostril of S. pneumoniae (range 51,000-88,000) and controls 77,250
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(51,000-80,000). Mean interval between vaccination and inoculation was 3.0 days (SD 0.1). Four participants (3%) carrying pneumococcus at baseline were excluded (Table S2) .
Carriage rates by conventional microbiology were consistently, though non-significantly higher in those receiving LAIV compared with control ( Fig. 2A and Table S3 ).
Results by molecular detection were similar, with statistically significant differences at day 2 (2.21±1.33 vs. 1.54±1.45 for LAIV and control respectively, p=0.03, Fig. 2B and Table S3 ). Table   Se ).
In colonized individuals, AUC of carriage density was increased in the LAIV group versus controls by both conventional microbiology (Fig. 2C , Table S4 ) and molecular detection ( Fig.   2D and Table S4 ), although statistical significance was only reached for the d2-d14 interval by conventional methods. However, amongst participants without viral coinfection, the AUC bacterial density was significantly increased between day 2 and days 7, 9 and 14 by molecular detection (p=0.03, p=0.04 and p=0.04 respectively), and between day 2 and day 14 by conventional microbiology (p=0.03, Table Sf ). Individuals' density curves are shown in Figure   S2 . (Table S5) . Median inoculation doses were 82,167 CFU/nostril (range 60,667-93,000) and 81,083 (60,667-93,000) for LAIV group and control group, respectively. Data from seventeen (10%) participants were excluded due to S. pneumoniae carriage at baseline (n=13) or other time points (n=4) (Table S6) .
Colonization density prior to vaccination (at day 2) was not different (mean±SD 1.89±1.97 and 1.82±1.36 respectively, p=0.84, Table S7 ).
There was no significant difference in the primary endpoint of AUC carriage density by conventional microbiology to day 14, (mean±SD 20.93±14.07 and 26.10±14.41 in LAIV and controls respectively, p=0.11, Fig. 3A and C, Table 2 ). AUC by molecular detection were 21.61±14.02 and 25.89±14.94 for LAIV and control groups respectively (p=0.15, Fig. 3B and D, Figure S3 .
Reflecting the AUC analysis, pneumococcal carriage density was consistently lower in LAIV versus controls at each time point from day 6 onwards, and was significantly different by molecular detection at day 27 (0.94±1.48 vs 1.64±1.49, p=0.03, Fig 3A and 
Discussion
We have studied for the first time the impact of a live viral vaccine on a common respiratory bacterial pathogen using a controlled human co-infection model.
Antecedent LAIV administration did not significantly alter overall pneumococcal acquisition rates, but caused significant transient effects on carriage. Increased carriage acquisition at day 2, and carriage density at days 2 through 14 were observed by molecular detection (PCR) after removal of participants with confirmed intercurrent (non-vaccine) viral co-infection.
We found no evidence of increased colonization rates, nor increased bacterial densities in those subjects already colonized when receiving LAIV. In fact, this scenario was associated with reduced carriage density and carriage rates at day 27, decreased AUC of carriage density to day 27, and earlier clearance of carriage compared with the control group.
Although our model describes colonization, the results are consistent with murine co-infection disease models of wild type influenza and pneumococcus, reinforcing that the precedence of pathogen exposure determines disease outcome: pneumococcus infection following influenza can exacerbate disease, whereas pneumococcus infection preceding influenza may reduce mortality.
densities, supported by the positive association of carriage density and pneumonia risk and severity. 13, 15, 16 LAIV has been extensively safety-proven. However, murine models demonstrate that live attenuated virus replication in the nasopharynx can increase density and duration of pneumococcal carriage. A randomized controlled trial in children showed an increased pneumococcal density following LAIV. 9 We observed similar effects: bacterial colonization density reached approximately 1 log 10 higher post bacterial inoculation, but only when LAIV preceded pneumococcal challenge. With the order reversed, bacterial density decreased and clearance was more rapid.
Our results suggest increased pneumococcal carriage density following LAIV. Although these were not statistically significant at every time point, the antecedent study was powered to detect changes in acquisition, not density: based on previous calculations, we would require twice the number of acquisitions per arm (80 instead of 40) to detect a 2-fold difference in bacterial titres at any individual time point. 17 For overall AUC bacterial density, post-hoc analysis suggests 50 colonized individuals per arm would be required to detect a 50% difference.
Three participants with laboratory confirmed influenza B infections (all controls) and one with rhinovirus (LAIV group), had among the highest bacterial densities of their cohorts. Given the strong association between influenza or rhinovirus infection and high bacterial carriage density, we performed a post-hoc sensitivity analysis. After removing these individuals, we detected statistically significant increases in densities in the LAIV group and, based on the AUC bacterial density analyses, a compelling pattern of increases across every time interval.
We used two complementary and consistent methods for bacterial detection; conventional microbiology and more sensitive PCR-based detection. While the latter may in some cases represent the persistence of bacterial DNA in the absence of viable pathogen, the persistence beyond one week suggests lower level colonisation (unmeasurable by conventional microbiology pneumoniae. We chose 1 log 10 as a clinically relevant density difference; in mice, increases in colonisation density even below this threshold leads to increased transmission.
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Potential weaknesses of these studies were their limited size, single centre administration, and use of only one Streptococcus pnuemoniae serotype. We are currently assessing other serotypes within our model to address this limitation. Our model also recruited adults who, due to previous exposure to wild type influenza, are likely to have neutralizing antibodies. Any LAIV effect may be more pronounced in children with lower antibody rates and titres, increased vaccine virus reproduction and shedding, and higher rates of natural pneumococcal carriage.
lead to a transient increased density of pneumococcal carriage in adults, and this effect could be more pronounced in infants and children due to the absence of antibodies in this target group.
These studies are novel in three ways: 1) the first study in humans that directly assessed the impact of a vaccine on an unrelated human pathogen; 2) the largest conducted vaccine testing studies using a controlled human infection model; 3) the first controlled co-infection model using two live pathogens.
Future studies should investigate whether LAIV-vaccinated children are more likely to transmit nasal bacteria to their immediate contacts. 21, 25 In future vaccine protection studies, we emphasize the importance of evaluating the effect on pathogens not directly targeted by the vaccine. In the antecedent study (2015/16), LAIV vaccination preceded pneumococcal inoculation by 3 days. In the concurrent study (2016/17), the order was reversed (Fig. 1 ).
Methods
Individuals were "carriage positive" if any nasal wash culture following experimental challenge contained S. pneumoniae serotype 6B. Carriage was detected by conventional culture and quantified by serial dilution from nasal washes performed at days 2,7,9 and 29 (antecedent study), and 2,6,9 and 27 (concurrent study We recorded adverse events until 30 days after inoculation using structured questionnaire at study visits, additional reports from participant-initiated consultation on our 24-hour study phoneline, and self-report of administration of "standby" antibiotics (provided to study participants for use if immediately required). Participants carrying S. pneumoniae at their penultimate or ultimate clinic visits received a 3-day amoxicillin course after final sampling. An independent data and safety monitoring committee with access to unblinded data provided oversight of the safety and conduct of the trial.
The area under the curve (AUC) for bacterial density was calculated starting from day 2 according to the trapezoid rule using values of [log 10 (bacterial density+1)] for each interval.
Missing densities were interpolated from the mean of flanking density values. Sequential missing values, and missing values at the end of a given interval, were extrapolated using the average change over that interval stratified by vaccine group, with zero as a lower limit. Interpolation did not result in qualitative or important quantitative differences in results (sensitivity analysis assessed effects by randomly drawing the change from the respective interval's Gaussian distribution around the mean-change, iterating over 1000 draws.)
Antecedent study: The primary endpoint was the proportion of carriage-positive participants detected by conventional microbiology. Secondary endpoints were; proportion of carriage at each time point, duration of carriage, density of carriage at each time point, AUC bacterial density to each time point, and each endpoint determined by molecular detection. With baseline carriage rates of 50% (expected based on prior data from our model), 73 participants in each arm were required for 80% power to detect a 50% relative increase in pneumococcal acquisition at any time point, after 10% drop-out.
Concurrent study:
The primary endpoint was AUC bacterial density to day 14 by conventional microbiology amongst carriers only. Secondary endpoints included: duration of carriage, carriage proportion and density at each time point, AUC bacterial density to each time point, and each endpoint determined by molecular detection. Based on density data from the antecedent study control arm, we required 78 colonised participants (requiring 156 inclusions overall assuming 50% carriage) to detect a unit increase in log 10 (AUC carriage d2-d14) with 80% power, after 10% drop-out.
Generalised linear models (GLM) compared carriage rates at any time point, the duration of colonization, and AUC bacterial density over each interval. Generalised estimating equations (GEE) compared carriage rates and pneumococcal density at each time point, with participant as cluster effect and assuming an exchangeable working correlation structure. Post-hoc sensitivity analyses excluded cases of confirmed concurrent viral infections (Influenza B n=3; rhinovirus n=1) identified by symptom-triggered clinical review. Comparisons were two sided, with p<0.05 considered significant. Analyses were performed in R v3.3.3 (R Foundation). We report the planned modified intention to treat (ITT) analysis which excludes participants not receiving the vaccine or pneumococcal inoculation, those not completing the minimum required follow-up visits (day 2 and 7), and those with S. pneumoniae carriage of non-experimental serotype before inoculation (both studies) and following inoculation (concurrent study only).
During the concurrent study, we detected a systematic vaccine dispensing error by a single practitioner which resulted in 13 participants in the LAIV arm not receiving the required dose.
Following advice from the trial steering group (TSG), after consultation with the Medicines and Healthcare-products Regulatory Agency, senior investigators were unblinded to prior allocations, and the trial was extended to allow the pre-specified number of LAIV allocations (n=73) to be reached 
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